A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

被引：1

作者：

Chng, Wee-Joo ^{[1
,2
]}

Lonial, Sagar ^{[3
]}

Morgan, Gareth J. J. ^{[4
]}

Iida, Shinsuke ^{[5
]}

Moreau, Philippe ^{[6
]}

Kumar, Shaji K. K. ^{[7
]}

Twumasi-Ankrah, Philip ^{[8
]}

Villarreal, Miguel ^{[8
]}

Dash, Ajeeta B. B. ^{[8
]}

Vorog, Alexander ^{[8
]}

Zhang, Xiaoquan ^{[8
]}

Suryanarayan, Kaveri ^{[8
]}

Labotka, Richard ^{[8
]}

Dimopoulos, Meletios A. A. ^{[9
]}

Rajkumar, S. Vincent ^{[7
]}

机构：

[1] Natl Univ, Canc Inst, Dept Hematol Oncol, Singapore, Singapore

[2] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore

[3] Emory Univ, Med Sch, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[5] Nagoya City Univ, Inst Med & Pharmaceut Sci, Dept Hematol & Oncol, Nagoya, Japan

[6] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[7] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[8] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[9] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece

来源：

BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期

关键词：

PROGRESSION-FREE SURVIVAL; ORAL IXAZOMIB; MOLECULAR ABERRATIONS; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; IMPROVES; CARFILZOMIB; PREDNISONE;

D O I：

10.1038/s41408-022-00768-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide-dexamethasone (Rd) vs placebo-Rd (TOURMALINE-MM1/-MM2) or ixazomib vs placebo (TOURMALINE-MM3/-MM4) in specific high-risk CAs. After a pooled median follow-up of 25.6 months, the hazard ratio (HR) for PFS with ixazomib- vs placebo-based therapy for high-risk patients was 0.74 (95% confidence interval [CI]: 0.59-0.93; median PFS [mPFS] 17.8 vs 13.2 months), and 0.70 (95% CI: 0.62-0.80; mPFS 26.3 vs 17.6 months) for complementary standard-risk patients. The HR for expanded high-risk patients was 0.75 (95% CI: 0.64-0.87; mPFS 18.1 vs 14.1 months), and 0.71 (95% CI: 0.59-0.85; mPFS 36.1 vs 21.4 months) for complementary standard-risk patients. The HR for PFS with ixazomib- vs placebo-based therapy was 0.68 in patients with t(4;14) (95% CI: 0.48-0.96; mPFS 22.4 vs 13.2 months), and 0.77 for patients with amp1q21 (95% CI: 0.63-0.93; mPFS 18.8 vs 14.5 months). A PFS benefit was demonstrated with ixazomib- vs placebo-based therapy regardless of cytogenetic status, with greatest benefit observed in patients with t(4;14) and amp1q21.

引用

页数：10

共 39 条

[1] Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response [J].

Abdallah, Nadine ;

Rajkumar, S. Vincent ;

Greipp, Patricia ;

Kapoor, Prashant ;

Gertz, Morie A. ;

Dispenzieri, Angela ;

Baughn, Linda B. ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis K. ;

Dingli, David ;

Go, Ronald S. ;

Hwa, Yi L. ;

Fonder, Amie ;

Hobbs, Miriam ;

Lin, Yi ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Warsame, Rahma ;

Siddiqui, Mustaqeem ;

Lust, John ;

Kyle, Robert A. ;

Bergsagel, Leif ;

Ketterling, Rhett ;

Kumar, Shaji K. .

BLOOD CANCER JOURNAL, 2020, 10 (08)

[2]

Amgen, 2021, KYPROLIS CARF HIGHL

[3] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients [J].

Avet-Loiseau, Herve ;

Bahlis, Nizar J. ;

Chng, Wee-Joo ;

Masszi, Tamas ;

Viterbo, Luisa ;

Pour, Ludek ;

Ganly, Peter ;

Palumbo, Antonio ;

Cavo, Michele ;

Langer, Christian ;

Pluta, Andrzej ;

Nagler, Arnon ;

Kumar, Shaji ;

Ben-Yehuda, Dina ;

Rajkumar, S. Vincent ;

San-Miguel, Jesus ;

Berg, Deborah ;

Lin, Jianchang ;

van de Velde, Helgi ;

Esseltine, Dixie-Lee ;

di Bacco, Alessandra ;

Moreau, Philippe ;

Richardson, Paul G. .

BLOOD, 2017, 130 (24) :2610-2618

[4] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma [J].

Avet-Loiseau, Herve ;

Fonseca, Rafael ;

Siegel, David ;

Dimopoulos, Meletios A. ;

Spicka, Ivan ;

Masszi, Tamas ;

Hajek, Roman ;

Rosinol, Laura ;

Goranova-Marinova, Vesselina ;

Mihaylov, Georgi ;

Maisnar, Vladimir ;

Mateos, Maria-Victoria ;

Wang, Michael ;

Niesvizky, Ruben ;

Oriol, Albert ;

Jakubowiak, Andrzej ;

Minarik, Jiri ;

Palumbo, Antonio ;

Bensinger, William ;

Kukreti, Vishal ;

Ben-Yehuda, Dina ;

Stewart, A. Keith ;

Obreja, Mihaela ;

Moreau, Philippe .

BLOOD, 2016, 128 (09) :1174-1180

[5] Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [J].

Avet-Loiseau, Herve ;

Leleu, Xavier ;

Roussel, Murielle ;

Moreau, Philippe ;

Guerin-Charbonnel, Catherine ;

Caillot, Denis ;

Marit, Gerald ;

Benboubker, Lotfi ;

Voillat, Laurent ;

Mathiot, Claire ;

Kolb, Brigitte ;

Macro, Margaret ;

Campion, Loic ;

Wetterwald, Marc ;

Stoppa, Anne-Marie ;

Hulin, Cyrille ;

Facon, Thierry ;

Attal, Michel ;

Minvielle, Stephane ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4630-4634

[6] No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades [J].

Chalopin, Thomas ;

Vallet, Nicolas ;

Theisen, Olivier ;

Ochmann, Marlene ;

Tiab, Mourad ;

Godmer, Pascal ;

Barin, Carole ;

Herault, Olivier ;

Gyan, Emmanuel ;

Le Gouill, Steven ;

Avet-Loiseau, Herve ;

Benboubker, Lotfi ;

Moreau, Philippe ;

Touzeau, Cyrille .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) :635-638

[7] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study [J].

Cohen, Yael C. ;

Magen, Hila ;

Lavi, Noa ;

Gatt, Moshe E. ;

Chubar, Evgeni ;

Horowitz, Nethanel ;

Kreiniz, Natalia ;

Tadmor, Tamar ;

Trestman, Svetlana ;

Vitkon, Roy ;

Rouvio, Ory ;

Shvetz, Olga ;

Shaulov, Adir ;

Ziv-Baran, Tomer ;

Avivi, Irit .

ANNALS OF HEMATOLOGY, 2020, 99 (06) :1273-1281

[8] del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma [J].

Corre, Jill ;

Perrot, Aurore ;

Caillot, Denis ;

Belhadj, Karim ;

Hulin, Cyrille ;

Leleu, Xavier ;

Mohty, Mohamad ;

Facon, Thierry ;

Buisson, Laure ;

Do Souto, Laura ;

Lannes, Romain ;

Dufrechou, Stephanie ;

Prade, Nais ;

Orsini-Piocelle, Frederique ;

Voillat, Laurent ;

Jaccard, Arnaud ;

Karlin, Lionel ;

Macro, Margaret ;

Brechignac, Sabine ;

Dib, Mamoun ;

Sanhes, Laurence ;

Fontan, Jean ;

Clement-Filliatre, Lauriane ;

Marolleau, Jean-Pierre ;

Minvielle, Stephane ;

Moreau, Philippe ;

Avet-Loiseau, Herve .

BLOOD, 2021, 137 (09) :1192-1195

[9] Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial [J].

D'Agostino, Mattia ;

Ruggeri, Marina ;

Aquino, Sara ;

Giuliani, Nicola ;

Arigoni, Maddalena ;

Gentile, Massimo ;

Olivero, Martina ;

Vincelli, Iolanda Donatella ;

Capra, Andrea ;

Mussatto, Chiara ;

Ledda, Antonio ;

Tacchetti, Paola ;

Musolino, Caterina ;

Cellini, Claudia ;

Patriarca, Francesca ;

Ballanti, Stelvio ;

Calogero, Raffaele ;

Musto, Pellegrino ;

Boccadoro, Mario ;

Gay, Francesca .

BLOOD, 2020, 136

[10] Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial [J].

Dimopoulos, Meletios A. ;

Spicka, Ivan ;

Quach, Hang ;

Oriol, Albert ;

Hajek, Roman ;

Garg, Mamta ;

Beksac, Meral ;

Bringhen, Sara ;

Katodritou, Eirini ;

Chng, Wee-Joo ;

Leleu, Xavier ;

Iida, Shinsuke ;

Mateos, Maria-Victoria ;

Morgan, Gareth ;

Vorog, Alexander ;

Labotka, Richard ;

Wang, Bingxia ;

Palumbo, Antonio ;

Lonial, Sagar .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) :4030-4041

← 1 2 3 4 →